Reviewing ATH cash flow report, they have $12.6mill cash in the...

Reviewing ATH cash flow report, they have $12.6mill cash in the kitty, which by the report will last a further 2.2 quarters going off current estimates.

Given this, it will cover the last 2 quarters of the trials and some, which by than we will have further data reports, and completion of the trials with results of these trials, which was also stated within the recent webinar, opening us right up to big pharm and others given good reports and FDA orphan drug approval.

ASX had its worst day of losses in 4yrs today, wiping $100b off super accounts.

Given the above, does ATH need to consolidate despite holders likely selling at a loss and current cash flow to cover the remainder of the trials ?...I'm in 2 minds.